Member Info for Hurst10

On top of all the excellent news next week, we have another M&A, AZN out shopping in the biotech sector, with Novartis rumoured to be counter bidding

108/ purchase just printed

Pre US opening we have M&A stepping up in the Biotech sector.
The majors will be in bidding war for this one.
:
The ADRs of Mereo BioPharma (MREO) jumped ~15% in the pre-market Monday after The Times reported that Anglo Dutch pharma giant AstraZeneca (NASDAQ:AZN) is considering a bid for the U.K.-based biotech.
AstraZeneca (AZN) already has a partnership with Mereo (MREO). According to the report, one of the other partners of the company including Novartis (NVS), OncXerna and Ultragenyx (RARE) is likely to rival AstraZeneca (AZN) in its bidding.

Now 5 x on the bid than offer

With FDA ruling on gene therapy, we will have a substantial re rating of Affyxell and the subsequent potential Nasdaq listing of the company, will have a total re valuation of the founders investment.
Could be a Korean gold mine

Good for the sector:

FDA backing Gene therapy
The unanimous backing of Bluebird's gene therapies by FDA panels last week not only throws that company a lifeline, it also gives a boost to a section of the biotech world that has taken a particularly big hit to sentiment. True, final approvals of the lentiviral projects are still pending, and reimbursement will be another issue, but comments at the hearings suggest that US physicians and patients are open to using gene therapies despite ongoing safety concerns, largely around the risk of cancer, and questions about lack of durability. For the first project, eli-cel, for a very rare childhood condition, lack of other options for those without a matched donor for stem cell transplant helped win the risk-benefit argument. A green light for beti-cel for beta thalassaemia also looks likely after the project impressed on durability, with some patients transfusion free after four years. Bluebird shares opened up 40%, but the company remains in dire financial straits.

From the Gene therapy press:
Drugs that act by modifying a patient?s genes are close to approval in the United States, and one is already available in Europe. The developments mark a triumph for the field of gene therapy, once considered controversial

Why

From the Gene therapy press:
Drugs that act by modifying a patient?s genes are close to approval in the United States, and one is already available in Europe. The developments mark a triumph for the field of gene therapy, once considered controversial

“ success of AVA6000 and cohort dose commencing at
180 mg/m” with US hospitals on board at that level, will have investors looking for and having Avacta signing up licensing deals en masse, during Q3 and Q4.
Clinical trials will start and then off course the Koreans coming up in the inside lane with their clinical trials.
It certainly will be an eventful Q3 and Q4!

Note the 3 to 1 in favour of the bid remains in place and the size buyer are bidding and buying at attractive prices.
Buy prints will be shown shortly and it will be difficult to get stock.
With the US Biotech bouncing back with the market and more M&A about to happen, Avacta looks ridiculously undervalued.

What is very clear here, is that we have consistent buying interest and most likely from a buyer building a size holding.
We have an upcoming AGM that will carry a statement, confirming scheduled progress with AVA6000 and AVA3396,if there had been any issues, the company would had informed the market.Novartis,Roche,PfizerSanofi,Johnson&Johnson and Astra Zeneca.The majors have $1.72trillion in M&A capacity.
We have continued expansion with AffyXell and new manufacturing partners in the fastest growing area in the sector, being cell and gene therapy with the majors throwing billions at the sector.
We are awaiting further update from LG Chem Life Sciences,with expected milestone payments and further update on any advances to clinical trials.
The diagnostic division will most likely have an update of progress with the CE marked AffidDX antigen test for consumer self-testing.
With the pandemic continue to spread with new variants,the use of self testing kit will be in high demand across the Continent.
We will most likely soon be inviting a new major institution to the shareholder list and it will not stop there.
The daily M&A business in the biotech sector will only speed things up for any institution building a holding in the company.
Companies such as Novartis,Roche,PfizerSanofi,Johnson&Johnson and Astra Zeneca are investing in the sector.
The majors have $1.72trillion in M&A capacity.
Six trading days left before the AGM statement,as I have said before, Avacta is the best thing out of Cambridge since Arm holdings.
BUY

Just sit tight and await AGM.
Perhaps it will be a case of not what the will say, rather what they did not say.
Just for the longer term shareholders.

LG and Daewoong

And the follow up RNS from the Koreans as well

75/, 25/ and 100/ printed after hours.

Just focus on the AGM and a significantly re rated SOP

Much clearer AVA6000 guidance and the majors will be circling and investors will start working out, how valuable the therapeutic division will be worth.

BEGO back bidding 5 in a minute

46/ and 57/ going through125-7 shortlyAGM around the corner.Plenty of news flow about to happen.Foolish to be underweight the stock this week!